Agitation process for preparing a carbetocin drug product
The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.
1. A method for preparing a carbetocin drug product comprising carbetocin or a pharmaceutically acceptable salt thereof with increased resistance to aggregation, wherein the concentration of carbetocin is about 1 mg/mL to about 70 mg/mL, comprising:
(a) dissolving carbetocin or a pharmaceutically acceptable salt thereof and one or more excipients chosen from a surface active agent, solubilizer, tonicity enhancer, an agent to adjust the pH, and combinations thereof to form an aqueous solution;
(b) agitating the aqueous solution from step (a) for a time period of hours to form aggregate-forming solids;
(c) removing the formed aggregate-forming solids from the agitated solution to form a post-agitation solution; and
(d) adding the post-agitation solution to a container to form a final drug product: wherein the carbetocin drug product has increased resistance to aggregation when tested with shaking stress compared to an aqueous solution of carbetocin that has not been treated according to steps (b) and (c).
2. The method of claim 1 , wherein the carbetocin drug product is substantially free of the aggregate-forming solids.
3. The method of claim 1 , wherein the aqueous solution comprising carbetocin comprises a surface active agent, which is a visco-elastic polymer that is a cellulose derivative selected from the group consisting of hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), and carboxy methyl ethyl cellulose (CMEC).
4. The method of claim 1 , wherein the solubilizer is a hydrotrope, amino acid, or cyclodextrin selected from the group consisting of sodium benzoate, sodium salicylate, sodium benzene sulfonate, sodium benzene disulfonate, sodium cinnamate, sodium 3-hydroxy-2-naphthoate, sodium para-toluene sulfonate, sodium cumene sulfonate, nicotinamide, N,N-diethylnicotinamide, N,N-dimethyl benzamide, para-aminobenzoic acid hydrochloride, procaine hydrochloride, caffeine, sodium alkanoate, urea, N,N-dimethyl urea, arginine, methyl-R-cyclodextrin, randomly methylated-β-cyclodextrin (RM-β-CD), sulfobutylether-β-cyclodextrin (SBE-β-CD), epichlorohydrin-β-cyclodextrin, and carboxy methyl epichlorohydrin beta cyclodextrin.
5. The method of claim 4 , wherein the hydrotrope is present in a concentration ranging from about 50 mM to about 500 mM.
6. The method of claim 3 , wherein the cellulose derivative is present in an amount ranging from 0.0075% to 0.05% w/v.
7. The method of claim 1 , wherein the excipient is chosen from sorbitol, ethylenediaminetetraacetic acid (EDTA), potassium sorbate, acetate, and combinations thereof.
8. The method of claim 1 , wherein the carbetocin is present in a concentration of about 10 mg/mL to about 40 mg/mL.
9. The method of claim 1 , wherein the carbetocin is present in a concentration of about 25 mg/mL to about 35 mg/mL.